Last reviewed · How we verify

Tiragolumab and atezolizumab

University Medical Center Groningen · Phase 3 active Small molecule

Tiragolumab and atezolizumab is a PD-1/PD-L1 inhibitor Small molecule drug developed by University Medical Center Groningen. It is currently in Phase 3 development for Non-small cell lung cancer, Renal cell carcinoma. Also known as: RO7538483.

Tiragolumab is a monoclonal antibody that targets TIGIT, while atezolizumab is a monoclonal antibody that targets PD-L1, both of which are involved in immune checkpoint inhibition.

Tiragolumab is a monoclonal antibody that targets TIGIT, while atezolizumab is a monoclonal antibody that targets PD-L1, both of which are involved in immune checkpoint inhibition. Used for Non-small cell lung cancer, Renal cell carcinoma.

At a glance

Generic nameTiragolumab and atezolizumab
Also known asRO7538483
SponsorUniversity Medical Center Groningen
Drug classPD-1/PD-L1 inhibitor
TargetTIGIT, PD-L1
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Tiragolumab and atezolizumab work by blocking the interaction between TIGIT and its ligands, and PD-L1 and its receptor PD-1, respectively, which can help to restore the body's immune response against cancer cells. This can lead to the activation of immune cells, such as T cells, which can then attack and kill cancer cells. By targeting these immune checkpoints, tiragolumab and atezolizumab can help to enhance the body's anti-tumor immune response.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tiragolumab and atezolizumab

What is Tiragolumab and atezolizumab?

Tiragolumab and atezolizumab is a PD-1/PD-L1 inhibitor drug developed by University Medical Center Groningen, indicated for Non-small cell lung cancer, Renal cell carcinoma.

How does Tiragolumab and atezolizumab work?

Tiragolumab is a monoclonal antibody that targets TIGIT, while atezolizumab is a monoclonal antibody that targets PD-L1, both of which are involved in immune checkpoint inhibition.

What is Tiragolumab and atezolizumab used for?

Tiragolumab and atezolizumab is indicated for Non-small cell lung cancer, Renal cell carcinoma.

Who makes Tiragolumab and atezolizumab?

Tiragolumab and atezolizumab is developed by University Medical Center Groningen (see full University Medical Center Groningen pipeline at /company/university-medical-center-groningen).

Is Tiragolumab and atezolizumab also known as anything else?

Tiragolumab and atezolizumab is also known as RO7538483.

What drug class is Tiragolumab and atezolizumab in?

Tiragolumab and atezolizumab belongs to the PD-1/PD-L1 inhibitor class. See all PD-1/PD-L1 inhibitor drugs at /class/pd-1-pd-l1-inhibitor.

What development phase is Tiragolumab and atezolizumab in?

Tiragolumab and atezolizumab is in Phase 3.

What are the side effects of Tiragolumab and atezolizumab?

Common side effects of Tiragolumab and atezolizumab include Fatigue, Nausea, Diarrhea, Cough, Pyrexia.

What does Tiragolumab and atezolizumab target?

Tiragolumab and atezolizumab targets TIGIT, PD-L1 and is a PD-1/PD-L1 inhibitor.

Related